Latest News in the pharma Industry

All

Apogenix presents data on novel Hexavalent TNF receptor agonists

Apogenix presents data on novel Hexavalent TNF receptor agonists

20 Mar 2017

Agonists for GIT, CD27 and CD40 receptors in development for cancer immunotherapy exhibit significant in vitro- and in vivo activities.

Read more 
Essentica is the largest high-technology, state-of-the-art plant for production of ethanol.

Essentica is the largest high-technology, state-of-the-art plant for production of ethanol.

20 Mar 2017

Read more 
New analysis shows Novartis Entresto improves glycemic control among heart failure patients with diabetes

New analysis shows Novartis Entresto improves glycemic control among heart failure patients with diabetes

19 Mar 2017

New use of insulin was also reduced by 29% among patients taking Entresto compared to enalapril-treated patients.

Read more 
Dementia Consortium funds Manchester-based team targeting immune system in search for new dementia treatments

Dementia Consortium funds Manchester-based team targeting immune system in search for new dementia treatments

19 Mar 2017

Team led by Dr David Brough awarded £191,757 by public-private initiative driving early-stage drug discovery programmes.

Read more 
Merck introduces Millipore Express high area filters for more effective processing and optimum yield

Merck introduces Millipore Express high area filters for more effective processing and optimum yield

19 Mar 2017

Greater filtration capacity with a smaller footprint than conventional filters, improving economics for biopharmaceutical manufacturing.

Read more 
Landmark outcomes study shows that Repatha  decreases LDL-C to unprecedented low levels

Landmark outcomes study shows that Repatha decreases LDL-C to unprecedented low levels

17 Mar 2017

Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible wit...

Read more 
Growing market for generics and liberalization of OTC medicines driving demand at CPhI Japan 2017

Growing market for generics and liberalization of OTC medicines driving demand at CPhI Japan 2017

16 Mar 2017

PIC/S membership accelerating international interest with market forecast to reach US$115bn by 2024.

Read more 
FDA approves Novartis' Kisqali as first-line treatment for HR+/HER2- metastatic breast cancer

FDA approves Novartis' Kisqali as first-line treatment for HR+/HER2- metastatic breast cancer

16 Mar 2017

Kisqali plus letrozole showed treatment benefit across all patient subgroups regardless of disease burden or tumour location.

Read more 
Bosch showcases new development for continuous manufacturing

Bosch showcases new development for continuous manufacturing

16 Mar 2017

The Xelum platform combines dosing, mixing, granulating and pressing, paving the way for more efficient tablet manufacturing.

Read more 
Shire receives European approval for label extension of Cinryze

Shire receives European approval for label extension of Cinryze

16 Mar 2017

Cinryze is the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics.

Read more 
Optimizing development resources for efficient product development

Optimizing development resources for efficient product development

15 Mar 2017

Nowadays, efficient process research and development are, more than ever, an absolute must for contract manufacturers and API manufacturers. New products/processes need to be pushed through to market readiness faster and faster. However, development de...

Read more 
POLPHARMA B2B - VISIT US DURING DCAT WEEK MARCH 20-23, 2017 IN NEW YORK CITY

POLPHARMA B2B - VISIT US DURING DCAT WEEK MARCH 20-23, 2017 IN NEW YORK CITY

15 Mar 2017

For a quality, service and partnership-focused organization like Polpharma, responding to the growing challenges of the pharma industry partners constitutes a key focus. Therefore, during the upcoming DCAT Week in New York City, we wish to talk to our ...

Read more